Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif

Bone

Volumn 79, Issue , 2015, Pages 131-142

  Zelenchuk, Lesya V ^a   Hedge, Anne Marie ^a   Rowe, Peter S N ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

ASARM peptide; FGF23; MEPE; Mineralization; Rickets; Sclerostin

Indexed keywords

ALKALINE PHOSPHATASE; BETA CATENIN; COLECALCIFEROL 24 HYDROXYLASE; FIBROBLAST GROWTH FACTOR 23; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; MESSENGER RNA; OXYGENASE; PHOSPHORUS; SCLEROSTIN; SODIUM PHOSPHATE COTRANSPORTER 2A; SODIUM PHOSPHATE COTRANSPORTER 2C; URIC ACID; VASCULOTROPIN; GLYCOPROTEIN; MEPE PROTEIN, MOUSE; PHOSPHOPROTEIN; SCLEROPROTEIN;

AGING; ARTICLE; ASARM MOTIF; BONE FORMATION RATE; BONE MASS; BONE MINERAL; BONE STRENGTH; BONE STRUCTURE; CALCIUM TRANSPORT; CARBOXY TERMINAL SEQUENCE; COL1ALPHA1 GENE; COMPARATIVE STUDY; CREATININE CLEARANCE; FRACTIONAL EXCRETION OF PHOSPHATE; GENE; GENOTYPE; GLOMERULUS FILTRATION RATE; HYPERPHOSPHATEMIA; HYPOMINERALIZATION; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; KIDNEY INTESTINAL PHOSPHATE REGULATION; MEPE GENE; MINERAL APPOSITION RATE; MINERALIZATION; MORPHOMETRICS; MOUSE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PHENOTYPE; PHEX GENE; PHOSPHATE TRANSPORT; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN MOTIF; PURINE METABOLISM; REGULATORY MECHANISM; RENAL SYSTEM PARAMETERS; SURVIVAL RATE; TRABECULAR BONE; URIC ACID URINE LEVEL; ANIMAL; BONE; C57BL MOUSE; DISEASE MODEL; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; PHOTON ABSORPTIOMETRY; POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ABSORPTIOMETRY, PHOTON; ANIMALS; BONE AND BONES; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION TESTS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOPOROSIS; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION;

EID: 84931273556     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.05.030     Document Type: Article

References (61)

1. Cauley J.A., Chalhoub D., Kassem A.M., Fuleihan Gel H. Geographic and ethnic disparities in osteoporotic fractures. Nat Rev Endocrinol 2014, 10(6):338-351.
2. Stompor T., Zablocki M., Lesiow M. Osteoporosis in mineral and bone disorders of chronic kidney disease. Pol Arch Med Wewn 2013, 123(6):314-320.
3. Rowe P.S., de Zoysa P.A., Dong R., Wang H.R., White K.E., Econs M.J., et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000, 67(1):54-68.
4. Rowe P.S. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 2012, 22(1):61-86.
5. Salmon B., Bardet C., Khaddam M., Naji J., Coyac B.R., Baroukh B., et al. MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia. PLoS ONE 2013, 8(2):e56749.
6. Staines K.A., Mackenzie N.C., Clarkin C.E., Zelenchuk L., Rowe P.S., MacRae V.E., et al. MEPE is a novel regulator of growth plate cartilage mineralization. Bone 2012, 51(3):418-430.
7. Boskey A.L., Chiang P., Fermanis A., Brown J., Taleb H., David V., et al. MEPE's diverse effects on mineralization. Calcif Tissue Int 2010, 86(1):42-46.
8. Rowe P.S., Kumagai Y., Gutierrez G., Garrett I.R., Blacher R., Rosen D., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004, 34(2):303-319.
9. Bresler D., Bruder J., Mohnike K.L., Fraser D., Rowe P.S.N. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 2004, 183:R1-R9.
10. Opsahl Vital S., Gaucher C., Bardet C., Rowe P.S., George A., Linglart A., et al. Tooth dentin defects reflect genetic disorders affecting bone mineralization. Bone 2012, 50(4):989-997.
11. David V., Martin A.C., Hedge A.M., Drezner M.K., Rowe P.S. ASARM peptides: PHEX-dependent & independent regulation of serum phosphate. Am J Physiol Renal Physiol 2011, 300(3):F783-F791.
12. Atkins G.J., Rowe P.S., Lim H.P., Welldon K.J., Ormsby R., Wijenayaka A.R., et al. Sclerostin is a locally acting regulator of late-osteoblast/pre-osteocyte differentiation and regulates mineralization through a MEPE-ASARM dependent mechanism. J Bone Miner Res 2011, 26(7):1425-1436.
13. Boukpessi T., Gaucher C., Leger T., Salmon B., Le Faouder J., Willig C., et al. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin. Am J Pathol 2010, 177(2):803-812.
14. David V., Martin A., Hedge A.M., Rowe P.S. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 2009, 150(9):4012-4023.
15. Martin A., David V., Laurence J.S., Schwarz P.M., Lafer E.M., Hedge A.M., et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008, 149(4):1757-1772.
16. Rowe P.S., Matsumoto N., Jo O.D., Shih R.N., Oconnor J., Roudier M.P., et al. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone 2006, 39(4):773-786.
17. Rowe P.S.N., Garrett I.R., Schwarz P.M., Carnes D.L., Lafer E.M., Mundy G.R., et al. Surface Plasmon Resonance (SPR) confirms MEPE binds to PHEX via the MEPE-ASARM-motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 2005, 36(1):33-46.
18. Gowen L.C., Petersen D.N., Mansolf A.L., Qi H., Stock J.L., Tkalcevic G.T., et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 2003, 278(3):1998-2007.
19. Zhang L., Choi H.J., Estrada K., Leo P.J., Li J., Pei Y.F., et al. Multi-stage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet 2014, 23(7):1923-1933.
20. Hsu Y.H., Kiel D.P. Clinical review: genome-wide association studies of skeletal phenotypes: what we have learned and where we are headed. J Clin Endocrinol Metab 2012, 97(10):E1958-E1977.
21. Zmuda J.M., Yerges-Armstrong L.M., Moffett S.P., Klei L., Kammerer C.M., Roeder K., et al. Genetic analysis of vertebral trabecular bone density and cross-sectional area in older men. Osteoporos Int 2011, 22(4):1079-1090.
22. Jemtland R., Holden M., Reppe S., Olstad O.K., Reinholt F.P., Gautvik V.T., et al. Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res 2011, 26(8):1793-1801.
23. Styrkarsdottir U., Halldorsson B.V., Gudbjartsson D.F., Tang N.L., Koh J.M., Xiao S.M., et al. European bone mineral density loci are also associated with BMD in East-Asian populations. PLoS ONE 2010, 5(10):e13217.
24. Alam I., Padgett L.R., Ichikawa S., Alkhouli M., Koller D.L., Lai D., et al. Sibling family genes and bone mineral density: association and allele-specific expression in humans. Bone 2014, 64:166-172.
25. Reijnders C.M., van Essen H.W., van Rens B.T., van Beek J.H., Ylstra B., Blankenstein M.A., et al. Increased expression of Matrix Extracellular Phosphoglycoprotein (MEPE) in cortical bone of the rat tibia after mechanical loading: identification by oligonucleotide microarray. PLoS ONE 2013, 8(11):e79672.
26. Estrada K., Styrkarsdottir U., Evangelou E., Hsu Y.H., Duncan E.L., Ntzani E.E., et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012, 44(5):491-501.
27. Jain A., Fedarko N.S., Collins M.T., Gelman R., Ankrom M.A., Tayback M., et al. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 2004, 89(8):4158-4161.
28. Rowe P.S. The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled. Cell Biochem Funct 2012, 30(5):355-375.
29. Addison W., Masica D., Gray J., McKee M.D. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res 2009, 25(4):695-705.
30. Addison W., Nakano Y., Loisel T., Crine P., McKee M. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite - an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 2008, 23(10):1638-1649.
31. Dobbie H., Unwin R.J., Faria N.J., Shirley D.G. Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant 2008, 23(2):730-733.
32. Marks J., Churchill L.J., Edward S.D., Unwin R. The phosphatonin Matrix Extracellular Phosphoglycoprotein (MEPE) inhibits renal intestinal phosphate transport in vivo. J Am Soc Nephrol 2008, 19(12):2313-2320.
33. Zelenchuk L., Hedge A., Rowe P.S. SPR4-peptide alters bone metabolism of normal and HYP mice. Bone 2015, 72:23-33.
34. Zelenchuk L.V., Hedge A.M., Rowe P.S. PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism. PLoS ONE 2014, 9(5):e97326.
35. Barros N.M., Hoac B., Neves R.L., Addison W.N., Assis D.M., Murshed M., et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Miner Res 2013, 28(3):688-699.
36. Campos M., Couture C., Hirata I.Y., Juliano M.A., Loisel T.P., Crine P., et al. Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J 2003, 373(1):271-279.
37. Shirley D.G., Faria N.J., Unwin R.J., Dobbie H. Direct micropuncture evidence that matrix extracellular phosphoglycoprotein inhibits proximal tubular phosphate reabsorption. Nephrol Dial Transplant 2010, 25(10):3191-3195.
38. Boukpessi T., Septier D., Bagga S., Garabedian M., Goldberg M., Chaussain-Miller C. Dentin alteration of deciduous teeth in human hypophosphatemic rickets. Calcif Tissue Int 2006, 79(5):294-300.
39. Gaucher C., Boukpessi T., Septier D., Jehan F., Rowe P.S., Garabedian M., et al. Dentin noncollagenous matrix proteins in familial hypophosphatemic rickets. Cells Tissues Organs 2009, 189(1-4):219-223.
40. Zhao M., Harris S.E., Horn D., Geng Z., Nishimura R., Mundy G.R., et al. Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J Cell Biol 2002, 157(6):1049-1060.
41. Yuan B., Takaiwa M., Clemens T.L., Feng J.Q., Kumar R., Rowe P.S., et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 2008, 118(2):722-734.
42. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25(7):1468-1486.
43. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2(6):595-610.
44. Ott S.M. Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol 2008, 3(Suppl. 3):S151-S156.
45. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29(9):e45.
46. Azam N., Zhang M.Y., Wang X., Tenenhouse H.S., Portale A.A. Disordered regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase gene expression by phosphorus in X-linked hypophosphatemic (hyp) mice. Endocrinology 2003, 144(8):3463-3468.
47. Fujiwara I., Aravindan R., Horst R.L., Drezner M.K. Abnormal regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase activity in X-linked hypophosphatemia: a translational or post-translational defect. J Bone Miner Res 2003, 18(3):434-442.
48. Ranch D., Zhang M.Y., Portale A.A., Perwad F. Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res 2011, 26(8):1883-1890.
49. Eisner C., Faulhaber-Walter R., Wang Y., Leelahavanichkul A., Yuen P.S., Mizel D., et al. Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int 2010, 77(6):519-526.
50. Makovey J., Macara M., Chen J.S., Hayward C.S., March L., Seibel M.J., et al. Serum uric acid plays a protective role for bone loss in peri- and postmenopausal women: a longitudinal study. Bone 2013, 52(1):400-406.
51. Sritara C., Ongphiphadhanakul B., Chailurkit L., Yamwong S., Ratanachaiwong W., Sritara P. Serum uric acid levels in relation to bone-related phenotypes in men and women. J Clin Densitom 2012, 16(3):336-340.
52. Nabipour I., Sambrook P.N., Blyth F.M., Janu M.R., Waite L.M., Naganathan V., et al. Serum uric acid is associated with bone health in older men: a cross-sectional population-based study. J Bone Miner Res 2011, 26(5):955-964.
53. Salmon B., Bardet C., Coyac B.R., Baroukh B., Naji J., Rowe P.S., et al. Abnormal osteopontin and matrix extracellular phosphoglycoprotein localization, and odontoblast differentiation, in X-linked hypophosphatemic teeth. Connect Tissue Res 2014, 55(S1):79-82.
54. Glassock R.J. The GFR decline with aging: a sign of normal senescence, not disease. Nephrol Times 2009, 2(9):6-8.
55. Lindeman R.D., Tobin J., Shock N.W. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985, 33(4):278-285.
56. Rowe J.W., Andres R., Tobin J.D., Norris A.H., Shock N.W. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976, 31(2):155-163.
57. Park S.E., Oh K.W., Lee W.Y., Baek K.H., Yoon K.H., Son H.Y., et al. Association of osteoporosis susceptibility genes with bone mineral density and bone metabolism related markers in Koreans: the Chungju Metabolic Disease Cohort (CMC) study. Endocr J 2014, 61(11):1069-1078.
58. Rivadeneira F., Styrkarsdottir U., Estrada K., Halldorsson B.V., Hsu Y.H., Richards J.B., et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009, 41(11):1199-1206.
59. Liu S., Brown T.A., Zhou J., Xiao Z.S., Awad H., Guilak F., et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 2005, 16(6):1645-1653.
60. Hassler N., Roschger A., Gamsjaeger S., Kramer I., Lueger S., van Lierop A., et al. Sclerostin deficiency is linked to altered bone composition. J Bone Miner Res 2014, 29(10):2144-2151.
61. Silswal N., Touchberry C.D., Daniel D.R., McCarthy D.L., Zhang S., Andresen J., et al. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab 2014, 307(5):E426-E436.